Sign inJoin waitlistJoin the waitlist

Shoba Navai

Associate Medical Director, Clinical Division (Outpatient), Cancer and Hematology Center · Baylor College of Medicine

Credentials: · ·

History

Clinical Division (Outpatient) · Baylor College of Medicine
Present
Baylor College of Medicine
Present
Baylor College of Medicine
Present

Pediatric Hematology/Oncology
Baylor College of Medicine
2013–2016
Pediatrics and Global Child Health
2010–2013
Baylor College of Medicine
2006–2010
Vanderbilt University

Research

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Journal of Clinical Investigation · 2016 · 595 citations
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
Case report · Nature Communications · 2020 · 155 citations
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
Leukemia · 2021 · 139 citations

Nabil Ahmed
9 papers
Meenakshi Hegde
8 papers
John Hicks
4 papers
Khaled Sanber
4 papers · 3 as a fellow
Malcolm Brenner
4 papers
Rajkumar Venkatramani
4 papers
Stephen Gottschalk
4 papers
Daniel Landi
3 papers · 1 as a fellow
Helen Heslop
3 papers
Kevin Bielamowicz
3 papers · 1 as a fellow
Sarah Whittle
3 papers
Andras Heczey
2 papers

Clinical trials

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
Principal investigator · Recruiting · Phase 1
Baylor College of Medicine
2026–2044
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Principal investigator · Recruiting · Phase 1
Baylor College of Medicine
2021–2043
T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors
Principal investigator · Active not recruiting · Phase 1
Baylor College of Medicine
2016–2037
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
University of Texas Southwestern Medical Center
2023–2027